Peptide History
The first GnRH agonist that taught doctors how to turn off hormone signals to fight cancer and help couples have babies
Buserelin is a man-made copy of a natural hormone that controls sex hormones in your body. It was one of the first drugs in its class, developed by Hoechst in the 1980s. Doctors use it to treat prostate cancer, endometriosis, and to help with IVF by controlling when eggs are released. It works by first giving a big signal to your pituitary gland, then turning off the hormone response completely.
Quick Facts
1982
Discovery Year
When this peptide was first identified
Peptide
Type
Compound classification
Approved and widely used
Status
Current regulatory status
Research compound
Primary Use
Main area of investigation
Injection
Administration
How this peptide is typically given
Peptide chain
Size
Molecular structure type
The Visionaries
Hoechst AG (now Sanofi), Frankfurt, Germany
Developer and manufacturer
Created buserelin as HOE-766 in the early 1980s
""
Hoechst AG Research Division, Frankfurt, Germany
Research scientist
Key researcher in GnRH agonist development at Hoechst
""
Sanofi-Aventis (now Sanofi), Paris, France
Current manufacturer
Now produces Suprefact worldwide after Hoechst merger
""
Hoechst AG Endocrinology Division, Germany
Pharmacology researcher
Published comprehensive review of buserelin's effects in 1990
""
The Journey
The Discovery
In the 1970s, doctors faced a tough choice.
In the 1970s, doctors faced a tough choice. Men with prostate cancer needed their testosterone shut down. Women with endometriosis suffered from painful tissue growing in the wrong places, fed by estrogen. The only answers were surgery, radiation, or strong medicines with awful side effects. Scientists asked: could we use the body's own hormone system against these diseases? The answer was hidden in the pituitary gland.
The Breakthrough
Researchers discovered that GnRH is the master control hormone.
Researchers discovered that GnRH is the master control hormone. It's a tiny string of amino acids that tells your pituitary gland to release two other hormones: LH and FSH. These hormones then tell your ovaries and testes to make sex hormones. Hoechst scientists realized they could make an artificial version of GnRH that would be super-potent. When you used it over and over, the body's sensors would get tired and shut down the whole system.
The Trials
Hoechst called their discovery HOE-766, later named buserelin.
Hoechst called their discovery HOE-766, later named buserelin. They tested it in cancer patients first. The results were surprising and powerful. Men with prostate cancer who received buserelin had the same hormone shutdown as men who had their testicles surgically removed. Women with endometriosis finally got relief. By 1982, the drug was approved in Germany. By the late 1980s, doctors all over Europe were using it.
The Crisis
Then came an unexpected discovery.
Then came an unexpected discovery. Doctors realized that buserelin could help couples trying to have babies through IVF. By shutting down natural hormone release at just the right time, they could control exactly when eggs grew and were released. This meant women could take hormone shots that made many eggs ready at once, instead of just one per month. Buserelin became a key part of IVF protocols worldwide.
The Legacy
Today, buserelin remains important for cancer treatment, endometriosis, and fertility help.
Today, buserelin remains important for cancer treatment, endometriosis, and fertility help. Scientists learned from buserelin's success and created even better drugs. But buserelin showed them the way. It proved that the body's own hormone system could be turned into a powerful medicine. Now sold as Suprefact across Europe and Asia, it helps thousands of patients every year find relief from serious diseases and achieve their dream of having children.
Years of Progress
1977
GnRH hormone structure fully understood by scientists
GnRH hormone structure fully understood by scientists
1979
Hoechst begins development of buserelin as HOE-766
Hoechst begins development of buserelin as HOE-766
1983
First clinical studies show success in prostate cancer patients
First clinical studies show success in prostate cancer patients
1985
Approval in UK and other European countries
Approval in UK and other European countries
1987
Doctors discover usefulness in endometriosis treatment
Doctors discover usefulness in endometriosis treatment
1988
IVF programs begin using buserelin for cycle control
IVF programs begin using buserelin for cycle control
1990
Comprehensive research review published in medical journals
Comprehensive research review published in medical journals
1995
Approval in Japan and other Asian countries
Approval in Japan and other Asian countries
2000
Buserelin nasal spray and injection forms both widely available
Buserelin nasal spray and injection forms both widely available
2005
Over 20 years of safety data compiled from millions of patients
Over 20 years of safety data compiled from millions of patients
2015
Still one of the most used GnRH agonists worldwide
Still one of the most used GnRH agonists worldwide
2020
Continues as first-line treatment for multiple conditions
Continues as first-line treatment for multiple conditions
2023
Remains approved and used across Europe and Asia
Remains approved and used across Europe and Asia
2025
Buserelin teaches new generations of doctors about hormone control
Buserelin teaches new generations of doctors about hormone control
1977
GnRH hormone structure fully understood by scientists
GnRH hormone structure fully understood by scientists
1979
Hoechst begins development of buserelin as HOE-766
Hoechst begins development of buserelin as HOE-766
1983
First clinical studies show success in prostate cancer patients
First clinical studies show success in prostate cancer patients
1985
Approval in UK and other European countries
Approval in UK and other European countries
1987
Doctors discover usefulness in endometriosis treatment
Doctors discover usefulness in endometriosis treatment
1988
IVF programs begin using buserelin for cycle control
IVF programs begin using buserelin for cycle control
1990
Comprehensive research review published in medical journals
Comprehensive research review published in medical journals
1995
Approval in Japan and other Asian countries
Approval in Japan and other Asian countries
2000
Buserelin nasal spray and injection forms both widely available
Buserelin nasal spray and injection forms both widely available
2005
Over 20 years of safety data compiled from millions of patients
Over 20 years of safety data compiled from millions of patients
2015
Still one of the most used GnRH agonists worldwide
Still one of the most used GnRH agonists worldwide
2020
Continues as first-line treatment for multiple conditions
Continues as first-line treatment for multiple conditions
2023
Remains approved and used across Europe and Asia
Remains approved and used across Europe and Asia
2025
Buserelin teaches new generations of doctors about hormone control
Buserelin teaches new generations of doctors about hormone control
The Science
Buserelin works through a clever trick that takes advantage of how your body learns. Your pituitary gland has sensors that listen for the hormone GnRH. When it hears the signal, it releases two other hormones called LH and FSH. These hormones tell your reproductive organs to make sex hormones. Buserelin is a fake GnRH that your pituitary cannot ignore. At first, it makes the pituitary work overtime. But after a few days, the pituitary gets tired. Its sensors stop responding. The release of LH and FSH drops to almost zero. Sex hormone production crashes. This is called desensitization. It's temporary. When you stop taking buserelin, your pituitary wakes back up.
Buserelin is a nine-amino-acid peptide (a short chain of amino acids)
Chemical Name
1239.4 grams per mole
Molecular Weight
Buserelin has changes at two positions that make it ten times stronger and longer-lasting than natural GnRH
How It's Different From GnRH
C60H86N16O13 (contains carbon, hydrogen, nitrogen, and oxygen atoms)
Chemical Formula
Global Impact
1982
Year buserelin was first
Year buserelin was first approved in Germany
40+ years
Safe clinical use in
Safe clinical use in millions of patients worldwide
3 main uses
Cancer treatment, endometriosis relief
Cancer treatment, endometriosis relief, and fertility help
80-90%
Effectiveness rate in suppressing
Effectiveness rate in suppressing sex hormones when used correctly
""
""
Research Stage
Research Stage
Research Stage
Research Stage
Be Inspired
Continue the legacy. The next breakthrough could be yours.